CARs incorporate antibody-based ligand-binding domains, which can recognize proteins on the cancer cell surface and transmit a signal through a synthetic CD3ζ-CD28 or CD3ζ-4-1BB intracellular domain. This evidence concerns the gene CD247 and cancer.